These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20497745)

  • 41. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
    Kang WY; Lee HW; Gwon MR; Cho S; Shim WS; Lee KT; Yang DH; Seong SJ; Yoon YR
    Drug Des Devel Ther; 2020; 14():2101-2111. PubMed ID: 32546973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
    Neumiller JJ
    Ann Pharmacother; 2012 Mar; 46(3):358-67. PubMed ID: 22318932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic modeling of simvastatin, nelfinavir and their interaction in humans.
    Methaneethorn J; Kunyamee P; Jindasri W; Wattanasaovaluk W; Kraiboot A; Lohitnavy M
    Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5715-8. PubMed ID: 25571293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
    Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
    Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
    Martin P; Gillen M; Ritter J; Mathews D; Brealey C; Surry D; Oliver S; Holmes V; Severin P; Elsby R
    Drugs R D; 2016 Mar; 16(1):93-107. PubMed ID: 26748647
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
    Greischel A; Binder R; Baierl J
    Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
    Methaneethorn J; Chamnansua M; Kaewdang N; Lohitnavy M
    Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5711-4. PubMed ID: 25571292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin.
    Lilja JJ; Neuvonen M; Neuvonen PJ
    Br J Clin Pharmacol; 2004 Jul; 58(1):56-60. PubMed ID: 15206993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Study of the drug-drug interaction between simvastatin and cisapride in man.
    Simard C; O'Hara GE; Prévost J; Guilbaud R; Masseé R; Turgeon J
    Eur J Clin Pharmacol; 2001 Jun; 57(3):229-34. PubMed ID: 11497338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
    Li J; Klemm K; O'Farrell AM; Guler HP; Cherrington JM; Schwartz S; Boyea T
    Curr Med Res Opin; 2010 Aug; 26(8):2003-10. PubMed ID: 20583949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
    Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
    Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.
    Li G; Zhao M; Qiu F; Sun Y; Zhao L
    Drug Des Devel Ther; 2019; 13():129-139. PubMed ID: 30587933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
    Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K
    J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.
    Nishio S; Watanabe H; Kosuge K; Uchida S; Hayashi H; Ohashi K
    Hypertens Res; 2005 Mar; 28(3):223-7. PubMed ID: 16097365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
    Ishiguro N; Shimizu H; Kishimoto W; Ebner T; Schaefer O
    Drug Metab Dispos; 2013 Jan; 41(1):149-58. PubMed ID: 23073734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
    Blech S; Ludwig-Schwellinger E; Gräfe-Mody EU; Withopf B; Wagner K
    Drug Metab Dispos; 2010 Apr; 38(4):667-78. PubMed ID: 20086031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.